Literature DB >> 15605464

Neuroimaging in leukodystrophies.

Peter B Barker1, Alena Horská.   

Abstract

The application of techniques based on in vivo magnetic resonance to the study of leukodystrophies is evaluated. Magnetic resonance imaging (MRI), the most important neuroimaging modality for patients with leukodystrophies, has proven invaluable for the detection of the extent and etiology of white-matter involvement, diagnosis, and monitoring of disease progression. Proton magnetic resonance spectroscopy, which can detect several brain metabolites, including those related to axonal function and myelination, can provide additional diagnostic and prognostic information and, in some cases, allows a rare insight into the biochemical pathology of leukodystrophies. The potential of other advanced magnetic resonance techniques, including diffusion tensor imaging, magnetization transfer contrast, and molecular imaging, is also discussed. In the future, anatomic and physiologic magnetic resonance techniques are expected to be integrated into a single examination that will provide a detailed characterization of white-matter diseases in children.

Entities:  

Mesh:

Year:  2004        PMID: 15605464     DOI: 10.1177/088307380401900801

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Classification of childhood white matter disorders using proton MR spectroscopic imaging.

Authors:  A Bizzi; G Castelli; M Bugiani; P B Barker; E H Herskovits; U Danesi; A Erbetta; I Moroni; L Farina; G Uziel
Journal:  AJNR Am J Neuroradiol       Date:  2008-05-15       Impact factor: 3.825

2.  Diagnostic algorithm for the differentiation of leukodystrophies in early MS.

Authors:  Wolfgang Köhler
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

3.  Magnetic resonance imaging and genetic investigation of a case of Rottweiler leukoencephalomyelopathy.

Authors:  Katrin Hirschvogel; Kaspar Matiasek; Katharina Flatz; Michaela Drögemüller; Cord Drögemüller; Bärbel Reiner; Andrea Fischer
Journal:  BMC Vet Res       Date:  2013-03-26       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.